The lung is a prototypic organ that was evolved to reduce immunopathology during the immune response to potentially hazardous endogenous and exogenous antigens. In this study, we show that donor CD4
The lung is a prototypic organ that was evolved to reduce immunopathology during the immune response to potentially hazardous endogenous and exogenous antigens. In this study, we show that donor CD4
+ T cells transiently induced expression of indoleamine 2,3-dioxygenase (IDO) in lung parenchyma in an IFN-γ-dependent manner early after allogeneic hematopoietic stem cell transplantation (HSCT). Abrogation of host IDO expression by deletion of the IDO gene or the IFN-γ gene in donor T cells or by FK506 treatment resulted in acute lethal pulmonary inflammation known as idiopathic pneumonia syndrome (IPS). Interestingly, IL-6 strongly induced IDO expression in an IFN-γ-independent manner when deacetylation of STAT3 was inhibited. Accordingly, a histone deacetylase inhibitor (HDACi) could reduce IPS in the state where IFN-γ expression was suppressed by FK506. Finally, L-kynurenine produced by lung epithelial cells and alveolar macrophages during IPS progression suppresses the inflammatory activities of lung epithelial cells and CD4 + T cells through the aryl hydrocarbon receptor pathway. Taken together, our results reveal that IDO is a critical regulator of acute pulmonary inflammation and that regulation of IDO expression by HDACi may be a therapeutic approach for IPS after HSCT.
acute lethal pulmonary inflammation | IFN-γ | Th2/Th17 cells | indoleamine 2,3-dioxygenase | aryl hydrocarbon receptor I ndoleamine 2,3-dioxygenase (IDO) is a rate-limiting enzyme of tryptophan catabolism along the kynurenine pathway. The immunosuppressive mechanism of IDO is mediated by depletion of tryptophan and/or the accumulation of catabolites collectively known as kynurenines (1) (2) (3) (4) (5) . Recently, L-kynurenine, a product of IDO, has been identified as an endogenous ligand for the aryl hydrocarbon receptor (AhR), which is a ligand-activated transcription factor belonging to the steroid receptor family (6, 7) . It is now clear that the IDO-AhR pathway contributes to immune homeostasis by promoting modulation of innate and adaptive immune responses. Whereas IFN-γ is the most prominent inducer of IDO in various cell types, IL-6 also can induce the enzyme expression in astrocytes and neuronal and cancer cells by stimulating the JAK/ STAT3 signaling pathway (8, 9) . By contrast, IL-6 has been implicated in the pathophysiology of Th17-mediated pulmonary inflammations such as idiopathic pulmonary syndrome (IPS) (10, 11) . Thus, the IL-6-STAT3 pathway might be immunosuppressive or immunostimulatory in a context-dependent way.
The lung was evolved to develop tolerance mechanisms to avoid severe immunopathology during the immune response to pathogens (12, 13) . High levels of IDO are expressed in the lung during microbial infections. IFNs seem to be required for IDO expression by microbial components (14, 15) and IDO expressed in epithelial cells prevents immunopathology mediated by Th cells after microbial infections (16) . It is clear that defects in IDO expression in cystic fibrosis and granulomatous disease is associated with unchecked inflammation caused by infections (16, 17) . However, the function of IDO in noninfectious acute pulmonary inflammation remains unclear.
A histone deacetylase inhibitor (HDACi) exhibits immunomodulatory activities as well as antitumor properties (18) . In murine models of hematopoietic stem cell transplantation (HSCT), administration of suberanilohydroxamic acid (SAHA; vorinostat) ameliorates acute graft-versus-host disease (GVHD) by reducing proinflammatory cytokines (19) . Subsequent studies show that HDACi-induced suppression of GVHD requires IDO expression in dendritic cells (DCs) (20) . Clinical trials of HDACi have reported a decrease in acute GVHD (21) . There are enhanced regulatory T cells (Tregs) in patients treated with SAHA (22) , showing a positive relationship between these cells and HDACi-primed DCs. Interestingly, acetylation of STAT3 is critical for IDO expression (22, 23) . However, which signal triggers STAT3 activation after HDACi treatment is not known in GVHD settings. In the present study, we provide evidence that IL-6 and HDACi are essential for IDO expression, which is protective from IPS. Clinically important, HDACi can inhibit IPS in the condition that IFN-γ expression is suppressed by a calcineurin inhibitor (CNI). This combination of Significance Indoleamine 2,3-dioxygenase (IDO) is a rate-limiting enzyme in the metabolism of tryptophan and plays critical roles in immune regulation to avoid severe immunopathology. We demonstrate that IFN-γ signaling in lung parenchyma prevents idiopathic pneumonia syndrome by inducing IDO expression; inhibition of deacetylation of STAT3 potentiates IDO expression induced by IL-6 in an IFN-γ-independent manner; inhibition of IDO expression by immunosuppressants can be reversed by a histone deacetylase inhibitor; and finally, L-kynurenine acts on lung epithelial cells and CD4 + T cells through the aryl hydrocarbon receptor to suppress their inflammatory activities. Our results indicate that proinflammatory IFN-γ and IL-6 expressed within a short time range early after pulmonary inflammation is indispensable in protecting the lung from devastating immunopathology.
GVHD prophylaxis may be effective in preventing general GVHD, because IFN-γ is beneficiary for IPS, but harmful for intestinal GVHD.
Results

Differential Expression of IDO in GVHD Target Organs by Donor
T-Cell-Derived IFN-γ. Although the function of IDO has been demonstrated in intestinal GVHD (24, 25) , its role in other GVHD target organs is unknown. Therefore, we initially examined the distribution of IDO expression in various GVHD target organs in three different allogeneic murine HSCT models. As previously described (24) , IDO was strongly expressed in the colon at day 7 after HSCT. Interestingly, IDO expression was also notably observed in the lungs in all of the different models (Fig. 1A) . However, the spleen and liver did not exhibit a visible increase in IDO expression. Quantitative real-time PCR analysis confirmed the differential expression patterns of IDO mRNA in these organs (Fig. 1B) . To further characterize IDO expression in the lung, we performed immunohistochemistry (IHC) and flow cytometry analysis. IHC revealed that IDO staining was observed mainly in the epithelial layer (Fig. 1C) and we further confirmed the expression of IDO in epithelial cells identified with EpCAM + using flow cytometry (Fig. S1A ). In addition to the identification of epithelial cells, the positive cells identified by IHC have been morphologically shown to be macrophages (Fig. 1C) . Indeed, analysis of immunofluorescent staining confirmed colocalization of IDO in EpCAM + or F4/80 + cells (Fig. 1D ). According to a previous protocol, we used anti-F4/80 and anti-CD11c to identify lung interstitial macrophages (IMs), alveolar macrophages (AMs), and DCs (26) . IDO was predominantly expressed in F4/80
AMs but not in the other cell types (Fig. S1B ). These data indicate that IDO expression is prominently induced in the lung and colon after HSCT, and the sources of IDO expression in the lung are predominantly epithelial cells and AMs.
Donor T-cell-derived IFN-γ has been regarded as a principle inducer of IDO expression in colon tissue after HSCT (24) . We next sought to determine whether IFN-γ of donor T cells induces IDO expression in the lungs of recipients after HSCT. In contrast to the recipients of WT T cells, IDO was not expressed in the lungs of the recipients of IFN-γ −/− T cells ( Fig. 2A) . Consistently, the absence of IDO was observed in the organ of the IFN-γ receptor −/− (IFN-γR
) that received WT donor T cells (Fig. 2B) . We also confirmed that IDO expression was limited in the H-2b + F4/80 + recipient cells using flow cytometry analysis (Fig. 2C ), indicating that donor T-cell-derived IFN-γ induces expression of IDO in the lungs of recipients after HSCT.
We next determined the kinetics of IDO and IFN-γ in the lung after HSCT. At day 5 after HSCT, IDO was expressed. IDO expression peaked at day 7 and subsequently decreased (Fig. 2D) . The kinetics of IFN-γ expression were similar to that of IDO (Fig. 2E) . Levels of IDO in the colon surged at day 7, declined to a basal level by day 14, and continued to increase thereafter (Fig. S1C) . IFN-γ showed a similar kinetics pattern of expression in the colon (Fig.  S1D) . Taken together, these data indicate that IDO is highly and transiently expressed at an early stage in the lung by donor T-cellderived IFN-γ after HSCT. After observing the induction of IDO expression in the lung after HSCT, we next investigated the effect of the enzyme activity on lung-and colon-specific GVHD. When GVHD was induced by a higher dose of donor T cells (5 × 10 6 per mouse), IDO −/− recipients exhibited more rapid mortality and higher clinical scores compared with WT recipients (Fig. 3A) . IDO −/− mice also had a markedly higher pathological score for lung GVHD at day 10 but WT and IDO −/− mice had an almost equal pathological score for intestinal GVHD (Fig. 3B) . Induction of GVHD with a lower dose of donor T cells (2 × 10 6 per mouse) resulted in acute lethality in a minor number of IDO −/− recipients but a majority of mice had late-stage mortality over 50 d (Fig. S2A) . Although the lung of IDO −/− recipients had a higher pathological score at day 35, its gap between the two groups was smaller compared with when GVHD was induced with a higher dose of donor T cells (Fig. 3B and Fig. S2B ). By contrast, intestinal GVHD was more severe in IDO −/− recipients at this time (Fig.  S2B) . Altogether, our results seem to indicate that acute lethality in IDO −/− recipients might be associated with severe IPS in the former model, whereas late-stage mortality in the later model might be largely due to intestinal GVHD.
Th2 and Th17 cells have been revealed as the pathogenic cell type using murine IPS models (27) (28) (29) . Indeed, expression of IL-4 and IL-17 was significantly increased with a different kinetic in the lung of IDO −/− recipients (Fig. 3C) . IDO −/− mouse lungs also exhibited an increasing expression pattern of proinflammatory cytokines, TNF-α and IL-6, as GVHD progressed (Fig. 3C ). However, expression of these cytokines was not so evident in the lungs of WT recipients (Fig. 3C ). In addition, we observed that proliferating Ki67
+ and IL-4-and IL-17A-producing CD4 + T cells were markedly increased in the lungs of IDO −/− recipients compared with WT recipients (Fig. 3 D-F) . We confirmed severe IPS in IDO −/− recipients that received chemotherapy conditioning or different types of donors such as Bm12 (only a single MHC class II gene mismatched) or 129 (MHC matched but minor histocompatibility antigen mismatched) (Fig. S3) .
Absence of IDO in the host did not affect the percentage of Tregs in the lung (Fig. S4A) . Analysis of FoxP3, IL-10, and TGF-β mRNA in the lung showed no difference in their expression between WT and IDO −/− recipients (Fig. S4B ). More importantly, depletion of donor Tregs did not deteriorate IPS or lung inflammation ( Fig. S4 C and D) . Taken together, our data indicate that induced IDO within the lung after HSCT effectively suppresses pathogenic Th2 and Th17 cell expansion in a Tregindependent manner, inhibiting IPS.
IFN-γ Administration Reduces IPS Mediated by IFN-γ
−/− Donor T Cells.
Recipients administered IFN-γ −/− donor T cells exhibit increased mortality compared with recipients administered WT donor T cells (27, 30) . Therefore, we addressed whether the absence of IDO expression is associated with the lung damage of the recipient given IFN-γ −/− donor T cells. To test this hypothesis, we administered recombinant IFN-γ at days 5 and 7 after HSCT to induce IDO expression. Restoration of IDO expression was observed in the lungs of the recipients of IFN-γ −/− donor T cells by administering IFN-γ (Fig. 4 A and B) . The mortality, the severe lung injury and the increased pathogenic cytokine levels in the lungs of the recipients administered IFN-γ −/− donor T cells were significantly decreased by IFN-γ treatment (Fig. 4 C-E). However, a treatment effect for IFN-γ was not observed in the IDO −/− recipients. We further confirmed the regulatory role of IFN-γ signaling in IPS using IFN-γR −/− recipients ( −/− recipient of IFN-γ −/− donor T cells displayed intestinal GVHD, as seen in WT recipients of WT donor T cells but injection of IFN-γ had no effect on intestinal GVHD severity ( Fig. S6A ), suggesting that there is an IFN-γ-independent pathogenic mechanism for intestinal GVHD in IDO −/− recipients.
CNI Treatment Seems to Deteriorate IPS Through Inhibition of IDO
Expression. CNIs potently inhibit IFN-γ secretion from T cells (31, 32) and are most widely used in the clinic for pharmacological GVHD prophylaxis (33) . We examined whether CNI treatment influences the development of IPS associated with the inhibition of IDO expression. Although general survival was statistically improved by FK506 treatment, we observed worse clinical GVHD scores in recipients of FK506 compared with recipients of the control treatment at an early stage (Fig. 5A ). In FK506-treated recipients, we found that lung injury was increased compared with control mice (Fig. 5B) . Furthermore, levels of pathogenic cytokines were increased in the lungs of FK506-treated recipients (Fig. 5C ). In contrast, FK506 treatment suppressed both early-and late-stage intestinal GVHD (Fig. S6C ). These data demonstrated that increased severity and lethality after FK506 treatment at an early period might be involved in IPS. Based on this observation, we further tested whether this lung injury effect of CNI was attributable to its ability to inhibit IDO expression through inhibition of IFN-γ production. In vivo administration of FK506 strongly inhibited expression of IDO in the lung (Fig. 5D ) but infusion of IFN-γ in FK506-treated recipients restored its expression (Fig. 5E ) and attenuated the lung injury (Fig. 5F ). However, this effect of IFN-γ treatment was not observed in the IDO −/− recipients (Fig. 5F ). These results demonstrated that treatment of FK506 contributes to IPS after HSCT and may be responsible for inhibiting IDO expression by inhibiting IFN-γ production.
HDACi Induces IDO Expression in an IFN-γ-Independent Manner. Although IFN-γ-mediated STAT1/IRF1 signaling is a critical intracellular pathway for IDO transcription, it has also been shown that enhancing STAT3 acetylation through HDAC inhibition can induce IDO expression in DCs (23) . To determine whether HDACi is capable of inducing IDO expression via an IFN-γ-independent mechanism, we administered two pan-HDACis, SAHA and SB939 (pracinostat), to recipients of IFN-γ −/− donor T cells. In contrast to vehicle treatment, up-regulation of IDO and acetylated STAT3 was clearly observed in the lungs of recipients treated with these inhibitors (Fig. 6 A and B) . Interestingly, peak levels of the IDO and acetylated STAT3 protein in the lung were more remarkably increased after SB939 treatment compared with SAHA treatment. Using quantitative real-time PCR analysis, we confirmed that SB939 exhibited a more potent capacity to induce IDO expression in the absence of IFN-γ compared with SAHA (Fig. 6C) . We next evaluated whether IPS induced by the lack of IFN-γ signaling can be prevented by the restoration of IDO expression by treatment with HDACi. Histopathology and survival data clearly revealed that treatment with SB939 in WT but not in IDO −/− mice prevented IPS (Fig. 6 D and E) . Although SAHA treatment ameliorated IPS, it failed to decrease mortality. These results indicated that HDACi administration induced IDO in the lungs of recipients in the absence of IFN-γ signaling, which prevented IPS. Moreover, our data demonstrated that SB939 may have a stronger ability to induce IDO and a stronger functional activity than SAHA.
Next, we determined the mechanism of IDO induction by the administration of HDACi in our HSCT model. We observed induction of IDO and increased levels of acetyl-STAT3 in the lungs of recipients of IFN-γ −/− donor T cells after treatment with SB939 but not in those of recipients of T-cell-depleted bone marrow (TCD-BM) only (Fig. 7A) . These data suggest that HDACi may require an unknown factor, which is secreted during strong lung inflammation, to acetylate STAT3 and subsequently induce IDO expression. To determine which factor contributes to the induction of STAT3 acetylation after treatment with SB939, we analyzed the cytokine environment in the lung because cytokines acetylate STAT3 via class I HDAC inhibitors (34) . IL-6, TNF-α, and IL-1β levels were significantly increased in the lungs of recipients of IFN-γ −/− T cells compared with recipients of TCD-BM only (Fig. 7B) . To identify the cytokine that contributes to the induction of IDO expression by HDACi, we performed in vitro experiments using the murine macrophage cell line RAW264.7. HDACi-induced IDO expression and STAT3 acetylation were dominant in the presence of IL-6 (Fig.  7C) . We further confirmed that in vivo blockade of IL-6 signaling with anti-IL-6R antibody or gp130 inhibitor SC144 markedly reduced SB939-induced IDO expression and STAT3 acetylation in the lung (Fig. 7 D and E and Fig. S7 ) and subsequently suppressed lung injury and inflammation (Fig. S7) .
We also examined whether HDACi treatment induced IDO expression in FK506-administered recipients. SB939 treatment in these mice restored IDO expression (Fig. 7F ) and attenuated the lung injury, but these effects were not observed in FK506-treated IDO −/− mice (Fig. 7G ). These data suggest that IDO expression should require sustained acetylation of STAT3 after its induction by IL-6 and that IDO in turn result in suppression of IL-6 expression. Taken together, these data suggest that CNIinduced IPS can be ameliorated by HDACi most likely via an IL-6-dependent mechanism.
Induction of IDO Expression Prevents IPS via AhR. IDO creates its antiinflammatory effects by metabolizing tryptophan into L-Kyn which binds and activates the immunomodulatory transcription factor AhR (6). We investigated whether AhR would be involved in the inhibitory effect of HDACi on IPS. Administration of SB939 resulted in markedly increased production of L-Kyn in the lung (Fig. 8A ). An AhR-specific antagonist CH-223191 completely abolished the expression of CYP1B1, an AhR target gene, but not IDO mRNA (Fig. 8B) , suggesting that SB939 may induce the expression of CYP1B1 transcription through the IDO-AhR axis. Importantly, CH-223191 abrogated SB939-induced suppression of lung injury and inflammation (Fig. 8 C  and D) . Administration of CH-223191 alone had no effect on GVHD survival and lung damage (Fig. 8C and Fig. S8 ). These results indicate that the inhibitory effect of HDACi on IPS may be mediated by the IDO-AhR signaling pathway. (D) Lungs were collected from each group of recipient mice on day 9 and stained with H&E (100×). (E) Cytokine mRNA levels in the lungs were measured on day 9. The relative expression was presented as a fold change to the control group (lungs of TCD-BM only) normalized to a fold value of 1. The data are one of three independent experiments. *P < 0.05; **P < 0.01. ) and graphs of histopathological scoring (Right) of the lung on day 9 are presented. The data are one of three independent experiments. *P < 0.05; **P < 0.01; ***P < 0.001.
There was a marked decrease in CYP1B1 expression in the lung and intestine of IDO −/− recipients after HSCT (Fig. S9) , confirming that production of L-Kyn is required for triggering the AhR signaling. We next wanted to investigate how the IDO-AhR pathway controls IPS. High levels of AhR expression were dominantly detected in CD4 + T cells and epithelial cells in the lung on 7 d after HSCT (Fig. 9A) . IFN-γ induced expression of IDO mRNA and consequent production of L-Kyn in primary lung epithelial cells (Fig. 9B) . IFN-γ also induced CYP1B1 mRNA expression in an IDO-dependent manner (Fig. 9B) . These results indicate that L-Kyn of epithelial cells and macrophages exerts its biological actions in response to cytokines in autocrine and paracrine ways. Consistent with this interpretation, we showed that L-Kyn blocked IL-1β-induced IL-6 expression in A549 lung epithelial cells but CH-223191 completely recovered IL-6 production (Fig. 9C) . Knockdown of the AhR gene also abolished the suppressive effect of L-Kyn on IL-6 production induced by IL-1β (Fig. 9D) .
To examine AhR signaling in CD4
+ T cells, we isolated AhRexpressing CD4 + T cells from the 7-d lungs of IDO −/− recipients. Treatment with L-Kyn suppressed proliferation of polyclonally activated CD4 + T cells (Fig. 9E ) and their production of IL-4 and IL-17 (Fig. 9F) . There was increased expression of CYP1B1 mRNA in CD4
+ T cells in response to L-Kyn (Fig. 9G) . Taken together, our data suggest that L-Kyn produced by lung epithelial cells and alveolar macrophages suppresses IPS mainly through its action on lung epithelial cells and CD4 + T cells. ). The recipients were treated with SAHA (50 mg/kg) or SB939 (25 mg/kg) i.p. once daily from day 0 to day 17. (Left and Right) Survival and clinical GVHD scores, respectively. The data are one of two independent experiments. *P < 0.05; ***P < 0.001. ). The recipients were treated with SB939 i.p. once daily from day 0 to day 9. (A) IDO and Ac-STAT3 were detected in the lung on day 9. (B) Cytokine mRNA levels in the lungs were measured on day 9. The relative expression was presented as a fold change to the control group (lungs of TCD-BM only) normalized to a fold value of 1. (C) RAW264.7 cells were treated with SB939 (0.5 μM) in the presence or absence of TNF-α (20 ng/mL), IL-1b (2.5 ng/mL), or IL-6 (10 ng/mL). IDO and Ac-STAT3 were detected by Western blotting. (D and E) The recipients were treated with anti-IL-6R mAb on days 3, 5, and 9 (D) or with SC144 every day from day 0 to day 9 (E). IDO and Ac-STAT3 were detected in the lung on day 9. 
Discussion
mRNA expression after transfer of IFN-γ
−/− CD4 + T cells, whereas IDO mRNA was present after transfer of WT CD4 + T cells (28) . In the present study, we observed clear expression of IDO protein in the lungs of recipients at 5-14 d after HSCT. In addition, severe lung injury was associated with higher lethality in IDO −/− recipients. The cause of the discrepancy between our data and Burman et al.'s data are not known but may be due to the difference in the levels of IDO in the lung depending on the experimental model used. Burman et al. (30) used granulocyte colony-stimulating factor (G-CSF)-mobilized donor splenocytes as a donor graft that exhibits relatively less IFN-γ production compared with a donor graft with isolated normal naïve T cells plus TCD-BM (35) . IDO and IFN-γ levels in the lung tissue were considerably reduced in the G-CSFmobilized donor grafts used by Burman et al. (30) compared with our HSCT model (Fig. S10) . Levels of IFN-γ might not reach the threshold required for IDO up-regulation in their study. Additionally, the chemical inhibition of IDO by 1-MT is by far less efficient than genotypic deletion used in the present study. Thus, our data indicate that the protective activity of IDO on IPS correlates with the levels of IDO expression (36) .
IDO is induced in various types of cells; however, it has a different mechanism of suppression depending upon cell type. IDO expression in antigen-presenting cells (APCs) such as DCs and macrophages contributes to peripheral immune tolerance by inhibiting T-cell expansion and inducing Treg responses (37) (38) (39) . However, IDO expression in nonimmune cell types, such as epithelial cells, can inhibit immune effector processes in local tissues to limit collateral damage (14, 15) . Our data indicate that IDO expression was mainly detected in the host lung epithelial cells and AMs rather than in DCs, which effectively inhibited the expansion of inflammatory T cells within the lung. However, Treg responses were not altered. These results demonstrate that IDO activity may inhibit local inflammatory responses but may not result in tolerance induction. IDO activity might be associated with epithelial cells, which mainly account for all of the IDO activity in the lung (14) , and these cells are the major cell type that responds to IFN-γ and is protective against IPS (28, 30) . Interestingly, IDO of epithelial cells seems to suppress inflammation at least partially by inhibiting their own ability to produce IL-6, through the L-Kyn-AhR axis, in response to a proinflammatory cytokine such as IL-1β (Fig. 9 C and D) . Thus, epithelial cells are likely to have a self-regulating system for inflammation. In addition, L-Kyn produced by epithelial cells and probably by AMs appears to inhibit the activities of pathogenic CD4 + T cells (Fig. 9 E and F) . Because IDO expression in the lung was high and transient in the early phase of lung diseases (ref. 14 and Fig. 2D) , the L-Kyn-AhR pathway seems to be critical in inhibiting early immune effector processes rather than tolerance induction. However, it is also possible to regulate the inflammatory T-cell-Treg balance through sustained IDO expression in AMs (40) . Further studies are needed to dissect the contribution of epithelial cells and AMs as a cellular source of IDO to protect against IPS.
In the clinic, CNI-based immune suppression is used as a standard protocol for GVHD prophylaxis (33) . Classically, CNIs downregulate IL-2 synthesis, which prevents Th1 and CD8 T-cell functions and IFN-γ synthesis (31, 32) . By contrast, cyclosphorin A (CsA) treatment promotes Th17 and Th2 responses after experimental lung transplantation and subsequently increases bronchiolitis obliterans (41) . A more recent study demonstrated that CsA treatment preferentially expands alloantigen-specific Th17 cells within the lung by promoting lung parenchyma-derived IL-6, which promotes IPS (11) . Therefore, we investigated whether CNIinduced IPS was associated with the regulation of IDO activity. Our results demonstrated that CNI exacerbates IPS by suppressing IDO expression as a result of down-regulation of IFN-γ production. Taken together, the study of Varelias et al. (11) and ours suggest that down-regulation of IFN-γ may cause dysregulated IL-6 and subsequent Th17 differentiation through inhibition of IDO expression.
IDO function in GVHD was initially demonstrated by Blazar and colleagues (24) . They observed increased mortality in IDO −/− mice. A higher pathological score for colon GVHD and heavier T-cell infiltration to the colon at day 27 after HSCT were associated with increased mortality in IDO −/− mice. Consistently, our results demonstrated that late-stage mortality seemed to be associated with severe intestinal GVHD in IDO −/− mice (Fig. S2) . Although Blazar and colleagues (24) did not investigate the cause of acute lethality observed in a small number of mice observed in their experiments, our data suggest that acute lethality may be due to severe IPS in IDO −/− recipients. Further studies will be warranted to reveal the causal relationship of IPS and intestinal GVHD with mortality after HSCT transplantation.
Interestingly, 10 consecutive injections of FK506 induced acute lethality in 40% mice but the rest of the mice survived until termination of the experiments (Fig. 5A) . Early mortality in these mice seemed to be caused by severe IPS (Fig. 5B and Fig. S6C ). Once FK506 administration was stopped, however, a majority of the mice that survived appeared to recover from IPS to some extent (Fig.  S6C) . FK506 treatment suppressed both early-and late-stage intestinal GVHD (Fig. S6C) . As a matter of fact, our results from kinetics studies of IFN-γ expression (Fig. 2E and Fig. S1D ) predicted these observations, because IFN-γ acted on both the lung and colon early after HSCT but predominantly on the colon when intestinal GVHD was fulminant late after HSCT. Our findings of . Recipients received SB939 (as in Fig. 7 ) and 10 mg/kg CH-223191 once daily from day 4 to day 8. Levels of L-Kyn (A) and IDO and CYP1B1 mRNA (B) in the lung were measured using ELISA and real-time PCR on day 9. (C) Representative images (100×, Left) and graphs of histopathological scoring (Right) of the lung on day 9. (D) Levels of cytokine mRNA in the lung were measured using real-time PCR on day 9. The relative expression was presented as a fold change to the control group (lungs of TCD-BM only) normalized to a fold value of 1. The data are one of three independent experiments. *P < 0.05; **P < 0.01; ***P < 0.001.
the deteriorating effect of FK506 on early IPS in our preclinical animal models may raise an issue for evaluating a general effect of immunosuppressants on early IPS in the clinic.
In this study, we found that administration of an HDACi potently induces IDO expression in the lungs of HSCT recipients in an IFN-γ-independent manner, resulting in the prevention of IPS. As clinical trials for HDACi that prevent acute GVHD are currently underway (21, 22) , our findings may have clinical implications. In this study, the pan-HDAC inhibitor SB939 was identified as a potential inducer of IDO expression and thus an inhibitor of IPS. In comparison with SAHA, SB939 appeared to exhibit a stronger ability to induce IDO expression both in vivo and in vitro. Consequently, the inhibitory effects of SB939 on IPS were significantly increased compared with SAHA. SB939 is a new orally active hydroxamate-based HDACi that is currently in phase II clinical trials and that potently inhibits class I, II, and IV HDACs with excellent pharmacokinetic properties (42, 43) . Compared with SAHA, SB939 exhibits increased oral bioavailability and half-life. In cancer models, SB939 accumulates in tumor tissue and induces sustainable inhibition of histone acetylation, which results in more enhanced antitumor efficacy than SAHA (42) . Because SB939 induces sustainable inhibition of HDAC activity, it may induce IDO more strongly than SAHA through the accumulation of acetylated STAT3 in the lung tissue. Our results suggest that SB939 might be a candidate HDACi for the prevention of IPS. STAT3 acetylation has been identified as the mechanism of HDACi-induced IDO expression (23) . Our data demonstrated that IL-6 signaling is required for the accumulation of acetyl-STAT3 by HDACi, which results in the induction of IDO expression. In response to cytokine treatment, STAT3 protein is activated via acetylation on a single lysine residue by histone acetyltransferase p300 and via phosphorylation (34) . The cytosolic acetylation of STAT3 results in protein dimerization and subsequent nuclear translocation followed by cytokine-stimulated DNA binding and transcriptional regulation. Because cytokinemediated STAT3 acetylation is reversible by type I HDACs, STAT3 acetylation is strongly increased by the inhibition of HDACs. Therefore, IL-6 can create a microenvironment suitable for IDO induction by HDACi treatment. Because dysregulated IL-6 is a major mediator of IPS by driving on Th17 differentiation (11), IL-6 seems to have a self-regulating mechanism of shutting down its own expression via the IDO-AhR pathway (Fig. 9 C and  D) . It is interesting that IL-6 is required for the conversion of a pathogenic microenvironment into a tolerogenic microenvironment through functional IDO induction in the lung. Like IFN-γ, IL-6 may have a proinflammatory or antiinflammatory function depending upon conditions such as timing and quantity of its production during immune responses. Collectively, our results suggest that the inhibition of HDAC could provide clinically feasible strategies for preventing IPS in a CNI-based clinical setting.
In summary, the results of the present study suggest that the induction of IDO expression occurs in host lung parenchyma of HSCT recipients in an IFN-γ-dependent or -independent manner. More importantly, HDACi derepresses the blockade of IDO induction by decreasing IFN-γ and increasing IL-6. Therefore, the addition of HDACis, such as SB939, in the immunosuppressive protocol might be a suitable therapeutic strategy for the prevention and treatment of IPS.
Materials and Methods
Mice. Effects of L-Kyn Treatment. A549 cells were transfected with AhR siRNAs or control siRNAs (Thermo Fisher Scientific) using Lipofectamine 2000 reagent (Invitrogen) at 37°C for 120 h according to the manufacturer's protocol. Transfected cells (1 × 10 6 cells per 3 mL) were stimulated with IL-1β (12.5 ng/mL) after a 48-h pretreatment with or without L-Kyn (300 μM) plus CH-223191 (10 μM) in a 60-mm dish (Corning Costar) at 37°C for 72 h. To test the effects of L-Kyn on T cells, lung tissues from perfused mice were chopped into small pieces and incubated with collagenase type IV (2.4 mg/mL; Sigma-Aldrich) for 1 h at 37°C. Cell fractions then were harvested using a 30% Percoll gradient. CD4
+ T cells were purified by AutoMACS-positive selection with anti-CD4 (L3T4) magnetic beads. Purified CD4 + T cells (1.5 × 10 6 cells per milliliter) were treated with soluble anti-CD3 (3 μg/mL) or recombinant human IL-2 (20 ng/mL; R&D Systems) with or without L-Kyn (300 μM) in a 96-well plate (Corning Costar) at 37°C for 72 h. During the final 15∼17 h, the cells were pulsed with [ Isolation of Alveolar Epithelial Cells. Primary alveolar epithelial cells were isolated as previously described (48) . In brief, dispase (Gibco-Invitrogen) was instilled into lung tissues of C57BL/6 mice via the trachea. The lungs were removed and incubated in a dispase-containing solution for 45 min at room temperature. The parenchymal tissue was carefully teased apart, and the cell suspension treated with DNase I (Sigma-Aldrich). Single-cell suspensions were obtained using a 70-and 40-μm cell strainer (BD Falcon). Alveolar epithelial cells were isolated by AutoMACS-negative selection with anti-CD45 and anti-CD146 magnetic beads (Miltenyi Biotec). The CD45 −
CD146
− cells were incubated for 48 h and washed to remove nonadherent cells. The purity of EpCAM + cells was 90-95%.
Statistical Analysis. The Kaplan-Meier product-limit method was used to obtain survival curves. Survival data were analyzed with the Mantel-Cox logrank test. Overall GVHD clinical scores were analyzed using two-way ANOVA with a Tukey post hoc test. The Student's t test was used for the statistical analysis of real-time PCR or in vitro data. A P value of <0.05 was defined as statistically significant. The data are presented as the mean ± SEM.
